Persona	l care pi	lans and	gly	ycaemic
---------	-----------	----------	-----	---------

- control: the role of body mass index
 - and physical activity

charge and the cough BMI (body mass index) and physical activity are implicated in diabetes in plications, it is unclear how these factors influence personalised care planning linked to caemic control. This study assessed the mediating effects of BMI and physical activity on tions between personalised care plans (PCPs) and glycated haemoglobin (HbA _{1c}) levels, are population-based data. Thou thod Outstrapping was used to analyse PCP, HbA _{1c} , BMI, and physical activity data from 3894 condents to the 2014 Health Survey for England, for whom HbA _{1c} data was available, ardless of diabetes status. This group comprised 1812 (46.5%) males, 17 and 2082
hough BMI (body mass index) and physical activity are implicated in diabetes inplications, it is unclear how these factors influence personalised care planning linked to caemic control. This study assessed the mediating effects of BMI and physical activity on tions between personalised care plans (PCPs) and glycated haemoglobin (HbA _{1c}) levels, are population-based data. thod Outstrapping was used to analyse PCP, HbA _{1c} , BMI, and physical activity data from 3894 bondents to the 2014 Health Survey for England, for whom HbA _{1c} data was available,
replications, it is unclear how these factors influence personalised care planning linked to caemic control. This study assessed the mediating effects of BMI and physical activity on tions between personalised care plans (PCPs) and glycated haemoglobin (HbA _{1c}) levels, ag population-based data. thod otstrapping was used to analyse PCP, HbA _{1c} , BMI, and physical activity data from 3894 condents to the 2014 Health Survey for England, for whom HbA _{1c} data was available,
caemic control. This study assessed the mediating effects of BMI and physical activity on tions between personalised care plans (PCPs) and glycated haemoglobin (HbA _{1c}) levels, ag population-based data. thod otstrapping was used to analyse PCP, HbA _{1c} , BMI, and physical activity data from 3894 bondents to the 2014 Health Survey for England, for whom HbA _{1c} data was available,
tions between personalised care plans (PCPs) and glycated haemoglobin (HbA _{1c}) levels, ag population-based data. thod Otstrapping was used to analyse PCP, HbA _{1c} , BMI, and physical activity data from 3894 bondents to the 2014 Health Survey for England, for whom HbA _{1c} data was available,
thod otstrapping was used to analyse PCP, HbA _{1c} , BMI, and physical activity data from 3894 condents to the 2014 Health Survey for England, for whom HbA _{1c} data was available,
thod otstrapping was used to analyse PCP, HbA _{1c} , BMI, and physical activity data from 3894 condents to the 2014 Health Survey for England, for whom HbA _{1c} data was available,
otstrapping was used to analyse PCP, HbA _{1c} , BMI, and physical activity data from 3894 bondents to the 2014 Health Survey for England, for whom HbA _{1c} data was available,
otstrapping was used to analyse PCP, HbA _{1c} , BMI, and physical activity data from 3894 bondents to the 2014 Health Survey for England, for whom HbA _{1c} data was available,
bondents to the 2014 Health Survey for England, for whom HbA _{1c} data was available,
ardless of diabetes status. This group comprised 1812 (46.5%) males, 17 and 2082
.5%) females, aged 16 to 90 (Mean = 51.68 years, SD = 17.25).
vults
ents with a PCP had higher HbA _{1c} levels compared to those without a care plan. BMI
uenced this relationship amongst patients aged 40 to 60; those with a PCP and higher
A _{1c} also tended to have higher BMI values. Physical activity did not affect the relationship
ween PCPs and glycaemic control.
nclusions
Inclusions II, but not physical activity, partly explained higher HbA_{1c} levels in patients with a PCP.

46	debate is needed on the role of physical activity in personalised care planning and glycaemic
47	control.
48	
49	KEY POINTS
50	• Patients with a PCP (personal care plan) have higher HbA _{1c} values.
51	• BMI partly explains higher HbA _{1c} levels in patients with a PCP.
52	• Physical activity is not implicated in the relationship between PCPs and HbA _{1c} levels
53	Given that population-based prospective evidence implicates physical activity in
54	diabetes-related complications, there is need for some debate on the role of physical
55	activity in personalised care planning and glycaemic control.
56	
57	
58	Key words
59	Personal care plan; glycaemic control; BMI; physical activity
60	
61	Acknowledgements
62	The author wishes to thank the UK Data Service for making the HSE data available
63	
64	
65	
66	
67	
68	
69	
70	

INTRODUCTION

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

Blood glucose control is a critical aspect of diabetes care (Jia, 2016). People with diabetes, or individuals experiencing hyperglycaemia (Godoy et al., 2012, Farrokhi et al., 2011) may be offered personal care plans (PCPs) (Coulter et al., 2013) to help them manage their blood glucose (Diabetes UK, 2009). A PCP usually consists of a written document outlining specific goals, and activities designed to achieve these objectives (Diabetes UK, 2009, Coulter et al., 2013, The Health Developer Network, 2016). PCPs reflect a partnership between the doctor/nurse and their patients (Diabetes UK, 2017), are essential for effective self-management (Jansen et al., 2015, Tarkin et al., 2008), and have been implicated in improved patient outcomes (Hird et al., 2015, Russell et al., 2008). PCPs are presumed to play an important role in HbA_{1c} (glycated haemoglobin) levels (Diabetes UK, 2009). Setting clear goals for glycaemic control (e.g., achievable HbA_{1c} targets), and designating specific actions to attain these objectives (e.g., weekly participation in a local sports programme), can help patients initiate and sustain key lifestyle changes essential for reducing HbA_{1c} (Coulter et al., 2013). A recent Cochrane review of the effects of personalised care planning in adults with long-term conditions found HbA_{1c} levels to be 0.24% lower in patients with a PCP, compared to those receiving usual care (Coulter et al., 2015). Thus, HbA_{1c} level is an important criterion that GPs consider in deciding which patients to offer a PCP (Diabetes UK, 2017). In 2015 Diabetes UK launched an 'Information Prescription' scheme to ensure diabetes patients who fail to meet HbA_{1c}, blood pressure and cholesterol targets receive a one-page PCP containing specific action plans for improving metabolic control (e.g., reducing dietary fat, performing 150 minutes of moderate aerobic activity per week, and strength exercises ≥ 2 days per week) (Diabetes UK, 2017, Diabetes UK, 2015a). Patients with high blood pressure, high total cholesterol-to-HDL (high density lipoprotein) ratios, and

high HbA_{1c} have a greater risk of developing complications, and hence are likely to benefit from personalised care (Diabetes UK, 2017). Information prescriptions are integrated into primary care IT systems, such as EMIS Web, so that GPs receive an automated alert if a specific patient is failing to meet their metabolic targets (Diabetes UK, 2015b). Diabetes UK literature suggests over 1000 diabetes patients a month use information prescriptions to manage their condition (Diabetes UK, 2015a). Information prescriptions can be considered a specific IT-based PCP designed to improve glycaemic control in diabetes patients with a high risk of complications (Diabetes UK, 2015a).

Glycaemic control is influenced by BMI (body mass index) and physical activity (Malnick and Knobler, 2006, Hu et al., 2014, Bhupathiraju and Hu, 2016, Gay et al., 2016, Cuenca-Garcia et al., 2012, Hamer et al., 2014). Lower BMI values are associated with better HbA_{1c} outcomes (Patiakas and Charalampous, 2010, Senechal et al., 2013, Diels et al., 2014). For example, one study of type 2 diabetes patients found that a decrease in waist circumference, and increased physical fitness, was associated with an increased likelihood of significant HbA_{1c} reductions (> 0.5%) (Senechal et al., 2013). A prospective study of data from a 1958 birth cohort revealed that early onset of overweight/obesity was implicated in a 23.9-fold increased risk of a HbA_{1c} value \geq 7% (Power and Thomas, 2011). An investigation of 2707 adults at risk from type 2 diabetes implicated higher amounts of moderate-to-vigorous physical activity in lower HbA_{1c} values (Gay et al., 2016). Moderate-to-vigorous has been found to predict improved metabolic outcomes, including HbA_{1c} levels, in healthy adults (Hamer et al., 2014).

BMI and physical activity affect the risk of complications in diabetes patients (Segula, 2014, Blomster et al., 2013). For example, obesity (i.e., BMI \geq 30) is strongly implicated in cardiovascular disease (Wilson et al., 2002), high blood pressure (Segula, 2014), and higher levels of LDL cholesterol (Varbo et al., 2015). Physical inactivity has been linked to impaired

renal function, increasing retinopathy, and other complications, in patients with type 1 diabetes (Waden et al., 2008). Evidence from a long-term prospective study of over 11,000 patients with type 2 diabetes found that moderate-to-vigorous levels of physical activity (of at least 15 minutes per week) at baseline was associated with a reduced incidence of cardiovascular events, microvascular complications, and mortality rates, over a 5-year period (Blomster et al., 2013).

Despite evidence implicating BMI/physical activity in HbA_{1c} levels (Senechal et al., 2013, Quirk et al., 2014), and diabetes complications (Blomster et al., 2013, Waden et al., 2008, Segula, 2014), it is unclear the extent to which these factors influence the relationship between PCPs and glycaemic control (Diabetes UK, 2017). Although BMI and physical activity are not part of the criteria for offering information prescriptions to patients, (Diabetes UK, 2015a), they nevertheless constitute key lifestyle changes recommended for lowering HbA_{1c} in personalised care planning (Diabetes UK, 2009, Diabetes UK, 2015a). Thus, it follows that HbA_{1c} reductions associated with having a PCP will be partly attributable to changes in BMI and/or levels of physical activity. Similarly, poor weight control, and/or failure to adhere to physical activity targets, may negative the influence of PCPs on glycaemic control.

Nurses typically form part of health care teams who work in partnership with patients to arrange and monitor PCPs (Coulter et al., 2013), including information prescriptions (Diabetes UK, 2015b, Diabetes UK, 2017). Guidance published by Diabetes UK makes provision for a health professional to be named on information prescriptions, with a statement specifically inviting patients to discuss and agree achievable HbA_{1c} targets with a doctor or nurse (Diabetes UK, 2015a). There is particular emphasis on controlling HbA_{1c} levels, in order to reduce the risk of complications (Diabetes UK, 2015a). Prescriptions makes specific reference to lifestyle factors, meaning patient consultations are likely to involve

conversations about BMI/physical activity, in relation to glycaemic control (Diabetes UK, 2015a). As both BMI and physical activity contribute significantly to HbA_{1c}, and related complications (Segula, 2014, Bhupathiraju and Hu, 2016, Blomster et al., 2013), it is essential to better understand how these factors influence the relationship between PCPs and HbA_{1c} levels (Diabetes UK, 2015a).

<u>AIM</u>

This study had two objectives. The first was to establish the association between PCPs and HbA $_{1c}$ levels. Current literature suggests HbA $_{1c}$ can be both a precursor and outcome of PCPs. In the former scenario HbA $_{1c}$ level is used as a criterion for offering PCPs to patients (Diabetes UK, 2015a, Diabetes UK, 2015b). In the latter situation, PCPs can help patients lower their HbA $_{1c}$ level (Coulter et al., 2015). Both directions of causality are valid. For the purposes of this paper, PCP status (i.e., whether or not a patient has a PCP) was treated as the 'predictor' variable, and HbA $_{1c}$ as the 'outcome' measure. This is consistent with a primary objective of personalised care – to improve glycaemic control (Coulter et al., 2015) – but does not preclude the use of HbA $_{1c}$ as a basis for offering PCPs to patients (Diabetes UK, 2015a, Diabetes UK, 2017). The second objective was to determine the extent to which BMI and physical activity explain any relationship between PCPs and HbA $_{1c}$ levels.

It was expected that (a) patients with PCPs will have lower HbA_{1c} levels compared to patients who had not agreed a care plan, and (b) BMI and physical activity will be implicated in this relationship, as mediating factors, such that the relationship between PCPs and HbA_{1c} is partly explained by BMI and physical activity. Thus, for example, lower HbA_{1c} values in patients with a PCP may partly reflect lower BMI scores, and/or greater physical activity levels in such patients. These hypotheses were tested both prior to and following adjustments for selected covariates, including diabetes status.

METHOD

Sample and procedure

This study analysed data on PCP status, HbA_{1c}, BMI, and physical activity, obtained from the 2014 *Health Survey for England* (HSE), an annual exercise that assesses health-related parameters and lifestyle factors in children and adults (Health Survey for England, 2014). The survey is commissioned by the Health and Social Care Information Centre, and consists of an interview (including self-administered questionnaires), followed by a visit by a nurse to collect biomedical data. The 2014 survey was completed by 8,077 adults (aged 16 and over), and over 2000 children (aged 0 to 15). The study reported here analysed data from 3894 adults for whom HbA_{1c} data was available. This group comprised 1812 (46.5%) males, and 2082 (53.5%) females, aged 16 to 90 (Mean = 51.68 years, SD = 17.25). The sample (92%) was predominantly Caucasian.

Measures

Glycated haemoglobin (HbA_{1c}) was based on non-fasting blood samples, and (for this study) calibrated in mmol/mol. HbA_{1c} data provides a measure of average blood glucose levels over the previous three months (Jia, 2016).

PCP status was assessed via two questions. Firstly, respondents were asked if (a) they had ever had a PCP-related discussion with a doctor/nurse regarding a long-term condition, 'Yes' (1)/ 'No or not sure' (0); and (b) whether they had agreed a PCP with a health professional during the past 12 months, 'no PCP agreed' (0)/ 'agreed a PCP < or > 12 months ago' (1). Responses to both items were combined to form a PCP index, with a higher indicating a better PCP status (e.g., discussed and/or agreed a PCP).

195	Physical activity was measured using the short IPAQ (International Physical Activity
196	Questionnaire) (Booth, 2000). The IPAQ/Short assesses three activity levels – walking,
197	moderate-intensity, and vigorous-intensity – across several domains (leisure time,
198	domestic/gardening, work/transport-based). Respondents receive a score for each level,
199	reflecting a summation of duration (minutes) and frequency (days). For the purposes of this
200	study, six separate scores were evaluated: total number of minutes usually spent per day, and
201	in the last 7 days, doing (a) 'vigorous-intensity' activities, (b) 'moderate-intensity' activities,
202	and (c) walking.
203	BMI was computed by dividing weight in kilograms by the square of height in metres
204	(kg/m^2) (Nuttall, 2015). Adults (aged > 16) were classified into the following groups: Less
205	than 18.5 'Underweight'; 18.5 to less than 25 'Normal'; 25 to less than 30 'Overweight'; 30
206	or more 'Obese'; 40 or more 'Morbidly obese'. The present study evaluated raw BMI scores,
207	for the purposes of hypotheses testing, and BMI groups (excluding the underweight category,
208	and combining obese and morbidly obese groups) for descriptive statistics.
209	Other variables assessed included blood pressure, and diabetes status. Blood pressure
210	was assessed using the Omron HEM 907 blood pressure monitor. Respondents were
211	classified into three groups: BP under 130/80, BP under 140/90, but not under 130/80, and
212	BP over 140/90. Respondents also indicated whether they had been diagnosed with high
213	blood pressure by a doctor; 'Yes' (1), 'No' (2). Diabetes status was assessed by asking
214	respondents if they currently have or have ever had diabetes, 'Yes' (1)/ 'No' (0).
215	
216	
217	Insert Table 1 about here
218	

220	
221	Insert Table 2 about here
222	
223	
224	Insert Table 3 about here
225	
226	
227	Insert Table 4 about here
228	
229	
230	RESULTS
231	Descriptive statistics (means/SD) are presented in <i>Table</i> 1. PCP data was available for 42.7%
232	(n = 1662) respondents. The vast majority of this subgroup (87.7%) had <i>not</i> agreed a PCP
233	with a health professional, while the remainder (12.3%) had agreed a PCP with a
234	doctor/nurse, \leq or \geq 12 months ago. These groups did not differ on measures physical activity
235	(both groups achieved the recommended ≥ 150 minutes of moderate-intensity activity), BMI
236	score (both groups classified as 'Overweight'), mental wellbeing score, or gender
237	distribution. There were also no group differences in the proportion who had been diagnosed
238	with high blood pressure by a doctor/nurse (over 98% of respondents had received this
239	diagnosis), and the proportion receiving earnings from employment or self-employment.
240	However, patients who had agreed a PCP were slightly younger, more likely to have been
241	diagnosed with diabetes, and had higher blood glucose levels (HbA _{1c}).
242	Table 2 shows the bivariate associations between variables. Patients who had
243	discussed and agreed a PCP with their doctor were younger, generated higher HbA1c values,
244	more likely to have been diagnosed with diabetes, and performed fewer minutes of moderate-

intensity physical activity during the previous 7 days. In addition to denoting diabetes status, higher HbA_{1c} values were associated with greater BMI, and fewer minutes of physical activity per day/week. Higher BMI values also depicted older age, doctor-diagnosed HBP, having ever had diabetes, and fewer minutes of physical activity. Gender differences are also noteworthy: overall, females had lower blood pressure, and lower levels of light (i.e., walking), moderate-, and vigorous-intensity physical activity per day, and during the past 7 days.

Hypothesis testing was performed using a bootstrapping SPSS dialogue (Hayes, 2013, Hayes, 2009). Bootstrapping was performed separately for each of the following age-related subgroups: aged up to 39; over 40; over 50; and over 60. In each bootstrapping model HbA_{1c} (mmol/mol) was entered as the outcome ('Variable Y'), while PCP status was treated as the predictor ('Variable X'). BMI and the six IPAQ/physical activity levels, were treated as mediator variables ('Variables M'). Diabetes status (whether participants had ever had diabetes), blood pressure (doctor-diagnosed), and gender, were treated as control variables (i.e., covariates). The conservative Sobel test was used to determine mediation. Results are shown in *Tables* 3 and 4.

0 to 39 years. PCP status directly predicted glycaemic control, such that people who had agreed a PCP had higher HbA_{1c} values compared to those without a PCP. Neither BMI nor physical activity mediated this relationship.

Over 40 years. PCP status directly predicted HbA_{1c}; patients with a PCP tended to have poorer glycaemic control. This relationship was mediated by BMI, whereby patients who had a care plan had both higher BMI and higher HbA_{1c} values, compared to those without a plan. This depicted a mediator effect because greater BMI was also associated with higher HbA_{1c} levels (see *Figure* 1). This indirect effect was significant based on the conservative Sobel test (z = 2.15, p < 0.05), and accounted for 13.1% of the total effect of

270 PCP status on HbA_{1c}. Controlling for diabetes status and other covariates attenuated the 271 indirect effect (Sobel test p > 0.05), but did not completely abolish it (see *Table 3*). Over 50 years. Having a PCP was associated with higher HbA_{1c} levels in this group. 272 273 This association was mediated by BMI, whereby those with a care plan had higher BMI, and poorer glycaemic control, compared to people without a PCP (see Figure 2). The Sobel test 274 275 for this indirect effect was significant (z = 2.06, p < 0.05). The mediator effect accounted for 18.2% of the total effect of PCP status on HbA_{1c}. Adjusting for covariates weakened but did 276 277 not entirely negate the indirect effect (*Table 3*). 278 Over 60 years. Although having a PCP predicted higher HbA_{1c} values, neither BMI 279 nor physical activity mediated this relationship. 280 281 Insert Figure 1 about here 282 283 284 Insert Figure 2 about here 285 286 **DISCUSSION** Contrary to what was hypothesised patients with a PCP had higher HbA_{1c} levels. However, 287 higher BMI scores partly explained this relationship (see Figures 1 and 2). Previous research 288 289 has implicated BMI in elevated HbA_{1c} (Power and Thomas, 2011, Senechal et al., 2013, 290 Patiakas and Charalampous, 2010). Interestingly, there was no evidence implicating physical activity in PCP – HbA_{1c} relations, despite previous studies associating exercise with 291 292 glycaemic control (Umpierre et al., 2011, Gay et al., 2016, Hamer et al., 2014). Previous research has implicated PCPs in *lower* HbA_{1c} (Coulter et al., 2015). An obvious 293 explanation for the higher HbA_{1c} levels observed here is the mediating effect of BMI. It is 294

possible PCPs may lead to elevated HbA $_{1c}$ values, if patients are gaining weight, perhaps due to noncompliance with PCP targets or action plans, and/or other factors, such poor doctorpatient interaction (Paternotte et al., 2015). Previous research shows a strong connection between higher BMI scores and higher HbA $_{1c}$, with one study linking elevated BMI scores in childhood to a 23.9-fold increased risk of a HbA $_{1c}$ \geq 7% later in life (Power and Thomas, 2011). Thus, patients with high HbA $_{1c}$ /BMI stand to benefit considerably from information prescriptions (Diabetes UK, 2015a) and other forms of personalised care (Coulter et al., 2013) that specifically target weight control. The fact that BMI mediated the PCP – HbA $_{1c}$ relationship specifically in 40 to 60 year olds suggests BMI plays a particularly important role in personalised care and glycaemic control in middle-aged patients (Owen et al., 2015).

Another possible explanation for the higher HbA_{1c} levels in patients with PCPs is that care plans tend to be offered to patients with poorer glycaemic control (Diabetes UK, 2015a). Offering PCPs to people with higher HbA_{1c} reflects current recommendations that information prescriptions should target individuals at high risk of complications (i.e., high HbA_{1c}) (Diabetes UK, 2017). The mediating effect of BMI may simply reflect the fact that patients with high HbA_{1c} also tend to have high BMI scores (Power and Thomas, 2011), and/or that GPs are simply more likely to offer PCPs to patients exhibiting both risk factors (Diabetes UK, 2009).

The fact that physical activity did not affect relations between PCPs and HbA_{1c} is worrying given that inactivity significantly increases the risk of complications (Waden et al., 2008, Blomster et al., 2013). Evidence from a long-term prospective study associates moderate-to-vigorous levels of activity with a reduced risk of cardiovascular problems, microvascular complications, and premature mortality (Blomster et al., 2013). Although other research suggests no link between exercise and complications (Makura et al., 2013), the availability of population-based prospective data (Blomster et al., 2013) suggests physical

inactivity should be an important factor in personalised care planning and glycaemic control. This seems particularly relevant to middle-aged/older patients. This demographic may find moderate-to-vigorous intensity exercises (e.g., fast cycling, running) particularly challenging, especially if conducted on a regular basis (Sparling et al., 2015), negating the glycaemic benefits (Kennedy et al., 2013). Other factors, such as increased calorie intake, or variations in insulin dosage, may also attenuate the effect of physical activity on HbA_{1c}, and should be carefully explored by doctors and patients when setting up PCPs (Kennedy et al., 2013).

This study has some limitations. Firstly, while BMI mediated the PCP – HbA_{1c} association, BMI is a poor index of body fat, or morbidity and mortality risk (Nuttall, 2015). Another problem is that data analysis did not control for every covariate relevant to PCP status, BMI, and HbA_{1c} (e.g., dietary intake, or insulin resistance). Additionally, there is uncertainty regarding the actual content of PCPs agreed with patients in this data set; due to the personalised nature of PCPs, the HSE does include individual HbA_{1c} targets, or recommended lifestyle changes. Furthermore, the HSE data analysed here pre-dates the launch of information prescriptions by Diabetes UK (Diabetes UK, 2015b). As this new personalised care tool is IT-based and can be deployed in a matter of minutes (Diabetes UK, 2017), it's impact on glycaemic control may be more dramatic than more generic PCP formats (Coulter et al., 2013). Finally, the cross-sectional nature of the design precludes inferences about the possible direction of causality.

This is the first study to examine how BMI and physical activity influence relations between personalised care planning and glycaemic control (Diabetes UK, 2017). The study suggests BMI partly explains higher HbA_{1c} levels in patients with a PCP. The irrelevance of physical activity in this context is worrying given recent population-based prospective evidence implicating exercise intensity in diabetes complications (Blomster et al., 2013). These findings are particularly important given the current emphasis on the use of

information prescriptions to improve patient outcomes (Diabetes UK, 2015b). If physical activity level is a precursor for complications (Blomster et al., 2013), then there needs to be some debate amongst doctors/nurses, in partnership with patients, on the role of exercise in personalised care regarding glycaemic control. **REFERENCES** Bhupathiraju, SN & Hu, FB 2016. Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications. Circulation Research, 118, 1723-1735. Blomster, JI, Chow, CK, Zoungas, S, Woodward, M, Patel, A, Poulter, NR, Marre, M, Harrap, S, Chalmers, J & Hillis, GS 2013. The influence of physical activity on vascular complications and mortality in patients with type 2 diabetes mellitus. Diabetes Obesity & Metabolism, 15, 1008-1012. Booth, M 2000. Assessment of physical activity: an international perspective. Res Q Exerc Sport, 71 Suppl 2, 114-20. Coulter, A, Entwistle, VA, Eccles, A, Ryan, S, Shepperd, S & Perera, R 2015. Personalised care planning for adults with chronic or long-term health conditions. The Cochrane Database Of Systematic Reviews. Coulter, A, Roberts, S & Dixon, A 2013. Delivering better services for people with long-term conditions: Building the house of care. London. Cuenca-Garcia, M, Jago, R, Shield, JPH & Burren, CP 2012. How does physical activity and fitness influence glycaemic control in young people with Type 1 diabetes? *Diabetic* Medicine, 29, e369-e376. Diabetes Uk 2009. Diabetes care and you: what diabetes care you can expect. Diabetes UK.

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

London: Diabetes UK.

369	Diabetes Uk. 2015a. Information Prescriptions [Online]. London: Diabetes UK. Available:
370	https://www.diabetes.org.uk/Global/professionals/INFO%20P%20RESOURCE_no%
371	20print%20marks.pdf [Accessed 8 February 2017].
372	Diabetes Uk. 2015b. Launch of Information Prescriptions [Online]. London: Diabetes UK.
373	Available: https://www.diabetes.org.uk/About_us/News/Launch-of-information-
374	prescriptions-for-people-with-diabetes/ [Accessed 8 February 2017].
375	Diabetes Uk. 2017. Information Prescriptions - Living Well [Online]. London: Diabetes UK.
376	Available: https://www.diabetes.org.uk/Guide-to-diabetes/Managing-your-
377	diabetes/information-prescriptions/ [Accessed 8 February 2017].
378	Diels, J, Angermund, R, Schroeder, M, Worbes-Cerezo, M & Thompson, G 2014. The
379	Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body
380	Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2
381	Diabetes Mellitus (T2DM). Value In Health: The Journal Of The International
382	Society For Pharmacoeconomics And Outcomes Research, 17, A334.
383	Farrokhi, F, Smiley, D & Umpierrez, GE 2011. Glycemic control in non-diabetic critically ill
384	patients. Best Practice & Research Clinical Endocrinology & Metabolism, 25, 813-
385	824.
386	Gay, JL, Buchner, DM & Schmidt, MD 2016. Dose-response association of physical activity
387	with HbA1c: Intensity and bout length. Preventive Medicine, 86, 58-63.
388	Godoy, DA, Soler, C, Videtta, W, Castillo Fuenzalida, L, Paranhos, J, Costilla, M, Pinero, G,
389	Jibaja, M, Melo, LJ & Latin-American Brain Injury, C 2012. Hyperglycemia in
390	nondiabetic patients during the acute phase of stroke. Arq Neuropsiquiatr, 70, 134-9.
391	Hamer, M, Stamatakis, E & Steptoe, A 2014. Effects of Substituting Sedentary Time with
392	Physical Activity on Metabolic Risk. Medicine and Science in Sports and Exercise,
393	46, 1946-1950.

394	Hayes, AF 2009. Beyond Baron and Kenny: Statistical mediation analysis in the new
395	millennium. Communication Monographs, 76, 408-420.
396	Hayes, AF 2013. Introduction to Mediation, Moderation, and Conditional Process Analysis:
397	A Regression-based Approach, New York, NY, The Guilford Press.
398	Health Survey for England 2014. Methods and documentation. Leeds: NatCen Social
399	Research, Department of Epidemiology and Public Health, UCL.
400	Hird, AE, Lemke, M, Turovsky, M, Malecki, V, Kumar, K, Deangelis, C, Chow, E & Ko, YJ
401	2015. Doctor, what are my options? A prospective cohort study of an individualized
402	care plan for patients with gastrointestinal cancer. Current Oncology, 22, E171-E177.
403	Hu, Y, Bhupathiraju, SN, De Koning, L & Hu, FB 2014. Duration of Obesity and Overweight
404	and Risk of Type 2 Diabetes Among US Women. Obesity, 22, 2267-2273.
405	Jansen, DL, Heijmans, M & Rijken, M 2015. Individual care plans for chronically ill patients
406	within primary care in the Netherlands: Dissemination and associations with patient
407	characteristics and patient-perceived quality of care. Scand J Prim Health Care, 33,
408	100-6.
409	Jia, WP 2016. Standardising HbA1c-based diabetes diagnosis: opportunities and challenges.
410	Expert Review of Molecular Diagnostics, 16, 343-355.
411	Kennedy, A, Nirantharakumar, K, Chimen, M, Pang, TT, Hemming, K, Andrews, RC &
412	Narendran, P 2013. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A
413	Systematic Review and Meta-Analysis. Plos One, 8.
414	Makura, CBT, Nirantharakumar, K, Girling, AJ, Saravanan, P & Narendran, P 2013. Effects
415	of physical activity on the development and progression of microvascular
416	complications in type 1 diabetes: retrospective analysis of the DCCT study. Bmc
417	Endocrine Disorders, 13.

418	Malnick, SDH & Knobler, H 2006. The medical complications of obesity. <i>Qjm-an</i>
419	International Journal of Medicine, 99, 565-579.
420	Nuttall, FQ 2015. Body Mass Index: Obesity, BMI, and Health: A Critical Review. <i>Nutrition</i>
421	Today, 50, 117-128.
422	Owen, CG, Kapetanakis, VV, Rudnicka, AR, Wathern, AK, Lennon, L, Papacosta, O, Cook,
423	DG, Wannamethee, SG & Whincup, PH 2015. Body mass index in early and middle
424	adult life: prospective associations with myocardial infarction, stroke and diabetes
425	over a 30-year period: the British Regional Heart Study. Bmj Open, 5.
426	Paternotte, E, Van Dulmen, S, Van Der Lee, N, Scherpbier, AJ & Scheele, F 2015. Factors
427	influencing intercultural doctor-patient communication: a realist review. Patient Educ
428	Couns, 98, 420-45.
429	Patiakas, S & Charalampous, C 2010. Correlation between the Glycated Hemoglobin (Hba1c)
430	Level, the Arterial Blood Pressure (Ap) and the Body Mass Index (Bmi) in Diabetic
431	Patients, and Evaluation of Its Utility as a C. Journal of Hypertension, 28, E300-
432	E300.
433	Power, C & Thomas, C 2011. Changes in BMI, duration of overweight and obesity, and
434	glucose metabolism: 45 years of follow-up of a birth cohort. Diabetes Care, 34, 1986-
435	91.
436	Quirk, H, Blake, H, Tennyson, R, Randell, TL & Glazebrook, C 2014. Physical activity
437	interventions in children and young people with Type 1 diabetes mellitus: a
438	systematic review with meta-analysis. Diabetic Medicine, 31, 1163-1173.
439	Russell, G, Thille, P, Hogg, W & Lemelin, J 2008. Beyond fighting fires and chasing tails?
440	Chronic illness care plans in Ontario, Canada. Annals of Family Medicine, 6, 146-153.
441	Segula, D 2014. Complications of obesity in adults: A short review of the literature. <i>Malawi</i>
442	Medical Journal, 26, 20-24.

443	Senechal, M, Swift, DL, Johannsen, NM, Blair, SN, Earnest, CP, Lavie, CJ & Church, TS
444	2013. Changes in body fat distribution and fitness are associated with changes in
445	hemoglobin A1c after 9 months of exercise training: results from the HART-D study.
446	Diabetes Care, 36, 2843-9.
447	Sparling, PB, Howard, BJ, Dunstan, DW & Owen, N 2015. Recommendations for physical
448	activity in older adults. BMJ (Clinical Research Ed), 350, h100.
449	Tarkin, IS, Sop, A & Pape, HC 2008. High-energy foot and ankle trauma: principles for
450	formulating an individualized care plan. Foot Ankle Clin, 13, 705-23.
451	The Health Developer Network. 2016. Care plan overview [Online]. London. Available:
452	http://developer.nhs.uk/library/systems/care-plans/care-plan-overview/ [Accessed 28
453	June 2016].
454	Umpierre, D, Ribeiro, PA, Kramer, CK, Leitao, CB, Zucatti, AT, Azevedo, MJ, Gross, JL,
455	Ribeiro, JP & Schaan, BD 2011. Physical activity advice only or structured exercise
456	training and association with HbA1c levels in type 2 diabetes: a systematic review
457	and meta-analysis. <i>JAMA</i> , 305, 1790-9.
458	Varbo, A, Benn, M, Smith, GD, Timpson, NJ, Tybjaerg-Hansen, A & Nordestgaard, BG
459	2015. Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Blood
460	Pressure as Mediators From Obesity to Ischemic Heart Disease. Circulation Research
461	116, 665-673.
462	Waden, J, Forsblom, C, Thorn, LM, Saraheimo, M, Rosengard-Barlund, M, Heikkila, O,
463	Lakka, TA, Tikkanen, H, Groop, PH & Grp, FS 2008. Physical Activity and Diabetes
464	Complications in Patients With Type 1 Diabetes The Finnish Diabetic Nephropathy
465	(FinnDiane) Study. Diabetes Care, 31, 230-232.

166	Wilson, PWF, D'agostino, RB, Sullivan, L, Parise, H & Kannel, WB 2002. Overweight and
167	obesity as determinants of cardiovascular risk - The Framingham experience.
168	Archives of Internal Medicine, 162, 1867-1872.
169	
170	
171	
172	
173	
174	
175	
176	
177	
178	
179	
180	
181	
182	
183	
184	
185	
186	
187	
188	
189	
190	




Figure 1 Mediating effect of BMI on the PCP – HbA_{1c} association in patients aged \geq 40 ($^ap<0.05$, $^cp<0.01$, $^bp<0.001$)




Figure 2 Mediating effect of BMI on the PCP – HbA_{1c} association in patients aged \geq 50 ($^ap<0.05$, $^cp<0.01$, $^bp<0.001$)

Table 1 – Descriptive statistics by PCP status.

		PCP status	
Variables	No PCP agreed	Agreed PCP < or > 12 months ago	P
Sample size (%)	1458 (87.7%)	204 (12.3%)	
Age	57.85 (16.87)	55.08 (15.94)	t(1660) = 2.25, p < 0.05
Gender (Male/Female)	638 (86.8%)/820 (88.5%)	97 (13.2%)/107 (11.5%)	Not Significant
HbA _{1c} (mmol/mol)	39.67 (10.32)	42.07 (13.98)	t(1660) = -2.36, p < 0.05
BMI (Body mass index)	28.52 (5.52)	29.13 (6.05)	Not Significant
Diabetes status (currently have, or ever had diabetes) (Yes/No)	172 (11.8%)/1284 (88.2%)	37 (18.1%)/167 (81.9%)	$\chi(1) = 6.50, p < 0.01$
High blood pressure – doctor diagnosed (Yes/No)	585 (98%)/12 (2%)	82 (98.8%)/1(1.2%)	Not Significant
Minutes VPA per day	57.62 (106.13)	52.20 (104.47)	Not Significant
Minutes MPA per day	64.00 (103.14)	50.33 (85.31)	Not Significant
Minutes Walking per day	78.18 (99.62)	85.04 (118.45)	Not Significant
Minutes VPA per week	214.06 (542.67)	217.42 (578.30)	Not Significant
Minutes MPA per week	279.64 (581.86)	212.51 (482.57)	Not Significant
Minutes Walking per week	424.20 (624.99)	456.83 (749.69)	Not Significant

Figures show the mean (+ standard deviation) or count (+ percentage). PCP = Personal care plan (status); MPA = Moderate-intensity activity; VPA = Vigorous-intensity activity; BMI = Body mass index.

Table 2 Bivariate correlations and descriptive statistics

Variables	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(13)	(14)
	` ´	,	` ´	, ,	, ,	` ′	` /	, ,	` ,	` ′	, ,	, ,	` ′	, ,
1) PCP index	-													
2) Age	-0.057^{a}	-												
3) Gender (M/F)	-0.037	0.011	-											
4) Hb _{A1c} mmol/ml	0.088^{b}	0.297^{b}	-0.016	-										
5) HBP (doctor)	-0.002	0.381^{b}	-0.034^{a}	0.255^{b}	-									
6) Diabetes (Y/N)	0.086^{b}	0.165^{b}	-0.022	0.599^{b}	0.203^{b}	-								
7) BMI score	0.047	0.163^{b}	-0.029	0.249^{b}	0.225^{b}	0.178^{b}	-							
8) VPA min p/d	-0.025	-0.111 ^b	-0.177^{b}	-0.030	-0.071 ^b	-0.038^{a}	-0.049^{b}	-						
9) MPA min p/d	-0.041	-0.074^{b}	-0.135 ^b	-0.053^{b}	-0.063 ^b	-0.061 ^b	-0.026	0.474b	-					
10) WK min p/d	0.012	-0.104^{b}	-0.075^{b}	-0.057^{b}	-0.082^{b}	-0.033	-0.057^{b}	0.345b	0.361^{b}	-				
11) VPA min p/w	-0.029	-0.096^{b}	-0.173^{b}	-0.023	-0.063 ^b	-0.041a	-0.034^{a}	0.907b	0.454^{b}	0.340^{b}	-			
12) MPA min p/w	-0.057^{a}	-0.075^{b}	-0.131 ^b	-0.039^{a}	-0.052^{b}	-0.047^{b}	-0.010	0.443b	0.905^{b}	0.368^{b}	0.485^{b}	-		
13) WK min p/w	0.002	-0.111 ^b	-0.073 ^b	-0.062^{b}	-0.086^{b}	-0.036^{a}	-0.059^{b}	0.345b	0.369^{b}	0.945^{b}	0.360 b	0.404^{b}	-	
$14) \geq 30 \min of$	-0.020	-0.225^{b}	-0.106^{b}	-0.171 ^b	-0.155 ^b	-0.116^{b}	-0.138^{b}	0.420b	0.431^{b}	0.164^{b}	0.311^{b}	0.335^{b}	0.156^{b}	-
MPA/VPA p/wk														

Note. HBP (High Blood Pressure), BMI (Body Mass Index), VPA (Vigorous-intensity physical activity), MPA (Moderate-intensity physical activity), WK (Walking), p/d (per day), p/w (per week). HBP reflects doctor-diagnosed cases. All physical activity variables denote total number of minutes spent on the specified activity. Superscripts: ${}^ap < .05$, ${}^bp < .01$, ${}^cp < .001$.

Table 3 – Mediating effects of BMI and physical activity on the PCP – HbA1c association, before and after adjusting for diabetes status and other covariates.

	Age groups								
Regression pathways	0-3	0-39		Over 40		Over 50		r 60	
	Effect	(CI)	Effect	(CI)	Effect	(CI)	Effect	(CI)	
Total effect of PCP on HbA1c	1.58ª	(0.34, 2.82)	1.84ª	(0.87, 2.81)	1.46ª	(0.39, 2.52)	1.60ª	(0.45, 2.74)	
Direct effect of PCP on HbA _{1c}	1.53 ^a	(0.28, 2.78)	1.57 ^a	(0.62, 2.53)	1.20 ^a	(0.15, 2.24)	1.48 ^a	(0.37, 2.59)	
Indirect effect of PCP on HbA1c via;									
Minutes VPA per day	0.03	(-0.16, 0.64)	-0.02	(-0.18, 0.02)	-0.03	(-0.22, 0.03)	-0.00	(-0.23, 0.05)	
Minutes MPA per day	-0.28	(-0.84, 0.02)	0.06	(-0.02, 0.23)	0.05	(-0.01, 0.26)	-0.01	(-0.23, 0.04)	
Minutes Walking per day	0.18	(-0.03, 1.16)	0.00	(-0.11, 0.31)	0.00	(-0.09, 0.18)	-0.01	(-0.24, 0.04)	
Minutes VPA past week	-0.01	(-0.48, 0.22)	-0.01	(-0.14, 0.05)	-0.01	(-0.20, 0.04)	-0.00	(-0.15, 0.08)	
Minutes MPA past week	0.29	(-0.02, 0.72)	-0.00	(-0.13, 0.13)	-0.01	(-0.19, 0.09)	0.00	(-0.05, 0.12)	
Minutes Walking past week	-0.18	(-1.01, 0.03)	-0.00	(-0.26, 0.12)	-0.00	(-0.10, 0.07)	-0.01	(-0.18, 0.06)	
BMI (body mass index)	0.02	(-0.10, 0.23)	0.24^{a}	(0.03, 0.48)	0.26^{a}	(0.05, 0.56)	0.17	(-0.08, 0.49)	

 ^{a}p <0.05 or CI range excludes '0'. PCP = Personal care plan (status); MPA = Moderate-intensity activity; VPA = Vigorous-intensity activity. BMI = Body mass index. For simplicity the table does not include the effects of variable *X* (PCP) on variables *M* (physical activity, BMI), and effects of variables *M* on variables *M* on variables *M* on variables of var

Table 4 – Mediating effects of BMI on the PCP – HbA1c association, before and after adjusting for diabetes status and other covariates.

	Age groups					
Regression pathways	Over 40		Over 50			
	Effect	CI	Effect	CI		
Total effect of PCP on HbA _{1c}	0.78ª	(0.02, 1.54)	0.72	(-0.12, 1.58)		
Direct effect of PCP on HbA1c	0.71	(-0.05, 1.47)	0.66	(-0.18, 1.52)		
Indirect effect of PCP on HbA1c via;						
BMI (body mass index)	0.07^{a}	(0.00, 0.18)	0.09 ^a	(0.01, 0.25)		

 ^{a}p <0.05 or CI range excludes '0'. Lower confidence interval for the BMI effect in the 'over 40 group' exceeded zero (0.003). For simplicity only the significant mediator variable (BMI) is included here; the table does not include the other M variables.